CN102395888B - 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估 - Google Patents

通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估 Download PDF

Info

Publication number
CN102395888B
CN102395888B CN201080016849.8A CN201080016849A CN102395888B CN 102395888 B CN102395888 B CN 102395888B CN 201080016849 A CN201080016849 A CN 201080016849A CN 102395888 B CN102395888 B CN 102395888B
Authority
CN
China
Prior art keywords
pct
antibiotics
induced
patients
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080016849.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102395888A (zh
Inventor
安德烈亚斯·贝格曼
约阿希姆·斯特鲁克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
Original Assignee
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40886944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102395888(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BRAHMS GmbH filed Critical BRAHMS GmbH
Priority to CN201510626744.9A priority Critical patent/CN105334330A/zh
Publication of CN102395888A publication Critical patent/CN102395888A/zh
Application granted granted Critical
Publication of CN102395888B publication Critical patent/CN102395888B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201080016849.8A 2009-04-14 2010-04-14 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估 Active CN102395888B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510626744.9A CN105334330A (zh) 2009-04-14 2010-04-14 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09157886.4 2009-04-14
EP09157886 2009-04-14
PCT/EP2010/002279 WO2010118855A1 (en) 2009-04-14 2010-04-14 Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510626744.9A Division CN105334330A (zh) 2009-04-14 2010-04-14 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估

Publications (2)

Publication Number Publication Date
CN102395888A CN102395888A (zh) 2012-03-28
CN102395888B true CN102395888B (zh) 2017-05-03

Family

ID=40886944

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080016849.8A Active CN102395888B (zh) 2009-04-14 2010-04-14 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估
CN201510626744.9A Pending CN105334330A (zh) 2009-04-14 2010-04-14 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510626744.9A Pending CN105334330A (zh) 2009-04-14 2010-04-14 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估

Country Status (15)

Country Link
US (3) US9046532B2 (https=)
EP (1) EP2419741B1 (https=)
JP (1) JP5650718B2 (https=)
CN (2) CN102395888B (https=)
CY (1) CY1122202T1 (https=)
DK (1) DK2419741T3 (https=)
ES (1) ES2751105T3 (https=)
HK (1) HK1221766A1 (https=)
HR (1) HRP20191862T1 (https=)
HU (1) HUE046182T2 (https=)
LT (1) LT2419741T (https=)
PL (1) PL2419741T3 (https=)
PT (1) PT2419741T (https=)
SI (1) SI2419741T1 (https=)
WO (1) WO2010118855A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2672561C2 (ru) * 2012-04-12 2018-11-16 Б.Р.А.Х.М.С Гмбх Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности
CN105528511A (zh) * 2014-10-25 2016-04-27 潘一琦 一种远程诊疗对比式问诊方法及其系统
CN107301319B (zh) * 2017-06-26 2021-02-26 济南市儿童医院 儿科临床及科研中抗菌药物使用危险评估系统
CN111656189A (zh) * 2017-12-20 2020-09-11 B.R.A.H.M.S有限公司 基于合并症患者的降钙素原的抗生素疗法指导
EP3502706A1 (en) * 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071583A2 (en) * 2004-12-23 2006-07-06 Biosite Incorporated Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
WO2008040328A2 (de) * 2006-10-01 2008-04-10 Brahms Aktiengesellschaft Diagnose von infektionen oder entzündungserkrankungen der atemwege und lunge assoziiert mit herzinsuffizienz
WO2009019230A2 (en) * 2007-08-03 2009-02-12 Brahms Aktiengesellschaft Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
DE19600875C1 (de) * 1996-01-12 1997-06-26 Brahms Diagnostica Gmbh Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse
ATE395364T1 (de) * 1999-12-22 2008-05-15 Dade Behring Marburg Gmbh Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung
DE60233949D1 (de) * 2001-08-20 2009-11-19 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
DE102005034174A1 (de) * 2005-07-21 2007-02-08 B.R.A.H.M.S Ag Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen
FR2894675B1 (fr) * 2005-12-14 2008-06-27 Assist Publ Hopitaux De Paris Distinction des meningites bacteriennes et virales

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071583A2 (en) * 2004-12-23 2006-07-06 Biosite Incorporated Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
WO2008040328A2 (de) * 2006-10-01 2008-04-10 Brahms Aktiengesellschaft Diagnose von infektionen oder entzündungserkrankungen der atemwege und lunge assoziiert mit herzinsuffizienz
WO2009019230A2 (en) * 2007-08-03 2009-02-12 Brahms Aktiengesellschaft Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised,single-blinded intervention trial;Mirjam Christ-Crain;《THE LANCET》;20040221;第363卷;第600-607页 *
Procalcitonin-guided antibiotic treatment in heart failure;Sir—Mirjam;《THE LANCET》;20040508;第363卷;第1555页 *

Also Published As

Publication number Publication date
PT2419741T (pt) 2019-11-04
EP2419741A1 (en) 2012-02-22
CN102395888A (zh) 2012-03-28
US9810699B2 (en) 2017-11-07
JP2012523573A (ja) 2012-10-04
HRP20191862T1 (hr) 2019-12-27
US20150247871A1 (en) 2015-09-03
CY1122202T1 (el) 2020-11-25
US20180052179A1 (en) 2018-02-22
PL2419741T3 (pl) 2020-01-31
DK2419741T3 (da) 2019-11-04
EP2419741B1 (en) 2019-07-31
HK1221766A1 (zh) 2017-06-09
LT2419741T (lt) 2019-11-11
SI2419741T1 (sl) 2019-12-31
WO2010118855A1 (en) 2010-10-21
JP5650718B2 (ja) 2015-01-07
HUE046182T2 (hu) 2020-02-28
US20120100635A1 (en) 2012-04-26
ES2751105T3 (es) 2020-03-30
CN105334330A (zh) 2016-02-17
US9046532B2 (en) 2015-06-02

Similar Documents

Publication Publication Date Title
CN102105794B (zh) 移植物衰竭和死亡的标志物
CN104303061B (zh) 患有疑似慢性心力衰竭的患者中不良事件的预后
CN102317790A (zh) 通过测定adm和bnp的水平在患有心力衰竭的患者中进行预后和风险评估
JP5827229B2 (ja) 有害事象の予後診断のためのプロカルシトニン
US20180052179A1 (en) Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
JP7502430B2 (ja) 敗血症管理
JP4734306B2 (ja) ナトリウム利尿ペプチドおよび胎盤増殖因子／可溶性ｖｅｇｆ受容体を用いた、妊婦での心疾患に関連した心機能不全と胎盤関連心機能不全とを区別するための方法
US8097424B2 (en) Method for predicting the outcome of a critically ill patient
JP7540074B2 (ja) Ｃｏｖｉｄ－１９患者の疾患重症度を予測するためのｇｄｆ－１５
JP7614477B2 (ja) 間質性肺炎のタンパク質診断バイオマーカー
CN117242350A (zh) 用于脓毒症的早期检测的il6标志物组
HK1167181B (en) Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
HK1167181A (en) Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
CN117597584A (zh) 用于脓毒症的早期检测的esm1标志物组合
HK1169165B (en) Procalcitonin for the prognosis of adverse events
HK1156104B (en) A marker for graft failure and mortality

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1167181

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1167181

Country of ref document: HK